Table 1. Characteristics of the Study Groups.

From: Possible Efficacy of Vaginal Progesterone on Asymptomatic Women with a Short Cervix after 24 Weeks of Gestation: A Historical Cohort Study in Japan

Period 1 Period 2 p
November 2015-March 2018 August 2018-August 2022
(n = 79) (n = 82)
Treatment for preventing and preparing preterm delivery      
 Ritodrine hydrochloride      
  Intravenous 79 (100.0) 0 (0.0) <0.001
  Oral 9 (11.4) 0 (0.0) 0.001
 Vaginal progesterone 0 (0.0) 82 (100.0) <0.001
 Intravenous magnesium sulphate 31 (39.2) 14 (17.1) 0.003
 Oral calcium channel blockers 2 (2.5) 4 (4.9) 0.682
 Antenatal steroid treatment 28 (35.4) 15 (18.3) 0.020
Maternal and delivery characteristics      
 Maternal age (years) 32.0 (29.0-35.0) 32.5 (29.0-36.0) 0.723
 Multiparity 46 (58.2) 45 (54.9) 0.751
 Race (nationality): Asian (Japanese) 79 (100.0) 82 (100.0) NA
 Body mass index 20.3 (18.4-22.0) 20.2 (19.2-22.4) 0.431
 Infertility treatment 9 (11.4) 20 (24.4) 0.040
 GA at maternal treatment start (weeks) 30.9 (28.8-31.7) 28.9 (26.8-30.7) <0.001
 CL at maternal treatment start (mm) 22.0 (12.5-31.0) 16.0 (11.3-19.0) 0.001
 Previous preterm delivery 12 (15.2) 14 (17.1) 0.832
 Cervical cerclage 5 (6.3) 2 (2.4) 0.271
 History of cervical conization 3 (3.8) 2 (2.4) 0.678
 Cesarean section 36 (45.6) 25 (30.5) 0.053
 Histological chorioamnionitis 25 (31.6) 19 (23.2) 0.289
Table 2. Comparison of Perinatal Outcomes between the Study Groups.

From: Possible Efficacy of Vaginal Progesterone on Asymptomatic Women with a Short Cervix after 24 Weeks of Gestation: A Historical Cohort Study in Japan

Period 1 Period 2 p
November 2015-March 2018 August 2018-August 2022
(n = 79) (n = 82)
GA at birth (weeks) 36.6 (32.3-37.6) 38.2 (36.2-39.1) <0.001
Preterm delivery (<37 weeks) 43 (54.4) 24 (29.3) 0.001
Preterm delivery (<34 weeks) 26 (32.9) 13 (15.9) 0.016
Interval from the diagnosis of short cervix to delivery <14 days 26 (32.9) 7 (8.5) <0.001
Interval from the diagnosis of short cervix to delivery <28 days 30 (38.0) 11 (13.4) 0.001
Birth weight (kg) 2.43 (1.83-2.96) 2.85 (2.41-3.18) 0.002
Male 43 (54.4) 44 (53.7) 1.000
1 min Apgar score 8.0 (7.0-8.0) 8.0 (8.0-8.0) 0.480
5 min Apgar score 9.0 (8.0-9.0) 9.0 (8.3-9.0) 0.184
Umbilical artery pH <7.10 0 (0.0) 1 (1.2) 1.000
Umbilical artery BE <−10.0 0 (0.0) 3 (3.7) 0.246
NICU admission 39 (49.4) 32 (39.0) 0.207
Neonatal      
 Intubation 14 (17.7) 5 (6.1) 0.028
 Surfactant administration 11 (13.9) 4 (4.9) 0.060
 Intraventricular hemorrhage 1 (1.3) 0 (0.0) 0.491
 Death 0 (0.0) 1 (1.2) 1.000
Table 3. Logistic Regression Analysis; Association between Periods 1 and 2 and Primary/Secondary Outcomes.

From: Possible Efficacy of Vaginal Progesterone on Asymptomatic Women with a Short Cervix after 24 Weeks of Gestation: A Historical Cohort Study in Japan

  Crude OR (CI) Adjusted OR (CI)
Primary outcomes  
 Preterm delivery (GA at birth <37 weeks) 0.35 (0.18-0.66) 0.43 (0.19-0.96)
 Preterm delivery (GA at birth <34 weeks) 0.38 (0.18-0.82) 0.39 (0.13-1.21)
 NICU admission 0.66 (0.35-1.23) 0.95 (0.42-2.15)
Secondary outcomes    
 Extension of pregnancy <14 days 0.19 (0.08-0.47) 0.21 (0.06-0.72)
 Extension of pregnancy <28 days 0.25 (0.12-0.55) 0.25 (0.09-0.74)
 Neonatal Intubation 0.30 (0.10-0.88) 0.17 (0.04-0.75)
 Neonatal surfactant administration 0.32 (0.10-1.04) 0.19 (0.03-1.14)
PAGE TOP